Business context and reporting period
RedHill Biopharma Ltd. filed this Form 6-K for September 2026. It reports transactions completed in August and the company’s stated stockholders’ equity position as of September 30; it does not include a full set of financial statements.
Key financial and operating information
- On August 27, 2026, RedHill sold its 70% interest in Talicia Holdings Inc. to an Apotex subsidiary. RedHill received $18.0 million upfront and may receive up to an additional $35.0 million based on worldwide net-sales milestones.
- On August 28, 2026, RedHill paid Ferring Pharmaceuticals $12 million upfront for exclusive global commercialization rights to Rebyota and exclusive U.S. commercialization rights to Clenpiq. The agreement also includes tiered royalties and potential sales-milestone and other contingent payments. Existing Rebyota inventory was acquired under deferred payment terms.
- RedHill stated that, following these transactions and other third-quarter movements, it believes stockholders’ equity exceeded $5 million as of September 30, 2026.
- The filing does not provide clear values for revenue, profit, cash flow, margins, debt, or overall liquidity.
Material changes and outlook
The company divested its Talicia Holdings interest and added commercialization rights for Rebyota and Clenpiq. Future proceeds from the Talicia sale depend on achieving sales milestones; the Ferring agreement entails royalties and potential contingent payments. No specific financial guidance or sales forecasts are provided.
Risks, contingencies, and other matters
- The potential additional Talicia consideration is contingent on worldwide net-sales milestones and is not guaranteed.
- Payments under the Ferring agreement include tiered royalties and potential milestone and other contingent amounts; the filing does not quantify them.
- RedHill entered into a transition services agreement with Apotex in connection with the Talicia transaction; its terms are not stated here.
- The 6-K is incorporated by reference into the company’s listed Form S-8 and Form F-3 registration statements.
Important facts to verify
- Whether Talicia sales milestones are achieved and any resulting payments are received.
- The commercial performance and economics of the Rebyota and Clenpiq rights, including royalties, contingent payments, and deferred inventory payments.
- RedHill’s reported financial statements and cash, debt, and liquidity position, which are not detailed in this filing.
- The basis and calculation supporting the company’s statement that stockholders’ equity exceeded $5 million.